Although atrial fibrillation is the most common MACE reported with BTK inhibitor treatment, ventricular arrhythmias, tachycardia, and sudden deaths have been reported with ibrutinib, acalabrutinib, and zanubrutinib [81,82,95,96,97], although their incidence is rare. This evidence concerns the gene BTK and atrial fibrillation.